Concepedia

Mehmet Altan

MA

Statistics

Publications

76

Citations

6.8K

H-Index

38

Active since

2014

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Baylor College of Medicine

Memorial Sloan Kettering Cancer Center

Yale University

Dana-Farber Cancer Institute

Mehmet Altan is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

2014–2025

76

Publications

76

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 604 citations · Full text

, , +17

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan et al. · Nature Medicine · 2018 · 455 citations

, , +14

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 367 citations · Full text

, , +17

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan et al. · Journal of Clinical Oncology · 2018 · 355 citations · Full text

, , +17

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Esther Aguilar, Biagio Ricciuti, Justin F. Gainor et al. · Annals of Oncology · 2019 · 336 citations

, , +17

1–5 of 76